The presence of busulfan metabolites and pharmacometabolomics in plasma drawn immediately before allograft infusion in hematopoietic cell transplant recipients.
Jeannine S McCuneSandi L NavarroLinda J RislerBrian R PhillipsSuping RenH Gary SchochK Scott BakerPublished in: Clinical and translational science (2023)
Busulfan is hepatically metabolized through glutathione (GSH) conjugation; in vitro, this process depletes hepatocyte GSH stores and generates the cytotoxic metabolite γ-glutamyldehydroalanylglycine (EdAG), which is too unstable to be quantitated in vivo. We sought to evaluate if pregraft (i.e., immediately before allograft infusion) concentrations of busulfan metabolites' and of endogenous metabolomic compounds (EMCs) representing the glutathione pathway were associated with clinical outcomes in hematopoietic cell transplant (HCT) patients receiving busulfan. The clinical outcomes evaluated were relapse, acute graft versus host disease (GVHD), chronic GVHD, non-relapse mortality, and neutrophil nadir. In pregraft samples obtained from patients immediately before allograft infusion, our objectives were to evaluate for: 1. The presence of busulfan and its metabolites tetrahydrothiophenium ion (THT+), tetrahydrothiophene 1-oxide, sulfolane, and 3-hydroxysulfolane (N=124); 2. EMCs using a global metabolomics assay (N=77). 3. The association of the busulfan metabolites and the EMCs with clinical outcomes. In the pregraft samples, busulfan and THT+ could not be detected. Tetrahydrothiophene 1-oxide, sulfolane, and 3-hydroxysulfolane were quantitated in 9.6%, 26%, and 58% of pregraft samples; their concentrations were not associated with clinical outcomes. Four pregraft EMCs were statistically significantly associated with the neutrophil nadir. The pregraft EMCs were not associated with the other clinical outcomes. In conclusion, busulfan's metabolites are present in patients' plasma immediately before allograft infusion; the neutrophil nadir is associated with pregraft EMCs. Future research should investigate the association of clinical outcomes with the concentrations of busulfans' metabolites and EMCs in the pregraft plasma from allogeneic HCT recipients.
Keyphrases
- allogeneic hematopoietic stem cell transplantation
- ms ms
- end stage renal disease
- low dose
- newly diagnosed
- ejection fraction
- chronic kidney disease
- single cell
- kidney transplantation
- acute myeloid leukemia
- prognostic factors
- mass spectrometry
- stem cell transplantation
- peritoneal dialysis
- type diabetes
- stem cells
- cell therapy
- intensive care unit
- coronary artery disease
- risk factors
- drug induced
- acute respiratory distress syndrome
- signaling pathway
- free survival